New Pharmaceuticals market report from Global Markets Direct: "Pancreatic Cancer - Pipeline Review, H1 2014"

Boston, MA -- (SBWire) -- 05/30/2014 --Pancreatic Cancer - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2014', provides an overview of the Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Celsion Corporation, Sanofi, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Inovio Pharmaceuticals, Inc., Gilead Sciences, Inc., Biotest AG, Daiichi Sankyo Company, Limited, Merck & Co., Inc., AbGenomics International, Inc., Takeda Pharmaceutical Company Limited, Symphogen A/S, Piramal Enterprises Limited, Aposense Ltd., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Samyang Holdings Corporation, Aphios Corporation, CK Life Sciences Int'l., (Holdings) Inc., Daewoong Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taiho Pharmaceutical Co., Ltd., Takara Holdings Inc., Teva Pharmaceutical Industries Limited, Vertex Pharmaceuticals Incorporated, Zeria Pharmaceutical Co Ltd, Genmab A/S, Aduro BioTech, Inc., Cyclacel Pharmaceuticals Inc., Celgene Corporation, Bayer AG, Incyte Corporation, Merck KGaA, Advaxis, Inc., Anavex Life Sciences Corp., ValiRx Plc, ImmunoCellular Therapeutics, Ltd., Immunomedics, Inc., Genfit SA, Lorus Therapeutics Inc., Bionomics Limited, Northwest Biotherapeutics, Inc., Patrys Limited, Peregrine Pharmaceuticals, Inc., Critical Outcome Technologies Inc., Oncogenex Pharmaceuticals, Inc., Pharmacyclics, Inc., Threshold Pharmaceuticals, Inc., CrystalGenomics, Inc., Natco Pharma Limited, Sareum Holdings plc, Microbio Co., Ltd., DiaMedica Inc., Oscotec Inc., MabVax Therapeutics, Inc., Nanobiotix SA, Morphotek, Inc., Isarna Therapeutics GmbH, Wilex AG, Aurigene Discovery Technologies Limited, Meabco A/S, Ganymed Pharmaceuticals AG, Philogen S.p.A., Quantum Pharmaceuticals, Multimmune GmbH, Nerviano Medical Sciences S.r.l., Hutchison MediPharma Limited, Erytech Pharma SA, Alethia Biotherapeutics Inc., Cellectis S.A., Ascenta Therapeutics, Inc., Phoenix Biotechnology, Inc., Heat Biologics, Inc., Antyra, Inc., Ambrx, Inc., OncoMed Pharmaceuticals, Inc., TetraLogic Pharmaceuticals, Kalos Therapeutics, Inc., Azaya Therapeutics Incorporated, Innopharmax Inc., MSM Protein Technologies, Inc., Jennerex Biotherapeutics, Inc., Stemline Therapeutics, Inc., BioCancell Therapeutics, Inc., Cornerstone Pharmaceuticals, Inc., Omnitura Therapeutics Inc., Pharminox Limited, Virobay Inc., NovaLead Pharma Pvt. Ltd., Immunotope, Inc., Esperance Pharmaceuticals, Inc., Omeros Corporation, TransTech Pharma, Inc., Welichem Biotech Inc., Globeimmune, Inc., NewLink Genetics Corporation, Pharma Mar, S.A., Quintessence Biosciences, Inc., AB Science, Adamis Pharmaceuticals Corporation, CureTech Ltd., Genelux Corporation, GlycoMimetics, Inc., Biothera, Inc., Medisyn Technologies, Inc., Keystone Nano, Inc., Pique Therapeutics, Arch Biopartners, Inc., Clovis Oncology, Inc., 3-V Biosciences, Inc., PharmAbcine, Inc., Cancer Therapeutics CRC Pty Ltd, Sunshine Biopharma, Inc., NuCana BioMed Limited, KAEL-GemVax Co., Ltd., Nuvilex, Inc., iCeutica, Inc., Incuron, LLC, Otsuka Holdings Co., Ltd., Mebiopharm Co., Ltd., Polaris Group, BiOrion Technologies B.V., DEKK-TEC, Inc., IkerChem S.L., Regulon Inc., TAU Therapeutics, LLC, Gradalis Inc., CytoVac A/S, SignPath Pharma Inc, BerGenBio AS, CytomX Therapeutics, Inc., Intezyne, Inc, Sialix, Inc., Igenica, Inc., Bexion Pharmaceuticals, LLC., Karyopharm Therapeutics, Inc., Apexigen, Inc., APIM Therapeutics AS, Kadmon Pharmaceuticals, LLC, centrose llc, Immodulon Therapeutics Ltd., NeoPharm Co., Ltd., CureFAKtor Pharmaceuticals. LLC, Kancera AB, Jasco Pharmaceuticals, LLC., Vaxeal Holding SA, Pharma Two B Ltd, Valens Therapeutics, Inc., Qu Biologics Inc., CZ BioMed Corp, IMPACT Therapeutics, Inc., LivTech, Inc., Io Therapeutics, Inc., Bioncotech Therapeutics S.L., Tactic Pharma, LLC, Immune Pharmaceuticals, Inc., Targovax AS, InvivoGen Therapeutics, Tolero Pharmaceuticals, Inc., StemPar Sciences, Inc., Biomar Microbial Technologies, Oncomatrix, S.L., Argon Pharma S.L., cCAM Biotherapeutics Ltd., Ability Pharma, SL, Pharmedartis GmbH, Precision Biologics, Inc., Oncology Research International Limited, MediaPharma s.r.l., TARGETOME, Huabo Biopharm Co., Ltd.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014
- Cervical Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Bladder Cancer - Pipeline Review, H1 2014
- Cancer Pain - Pipeline Review, H1 2014